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ABSTRACT 
 
B cells respond to antigens by engagement of their B cell antigen receptor (BCR) and of 
co-receptors through which signals from helper T cells or pathogen-associated molecular 
patterns are delivered. We show that the proliferative response of B cells to the latter 
stimuli is controlled by BCR-dependent activation of phosphoinositidyl 3-kinase (PI-3K) 
signaling. Glycogen synthase kinase 3β and Foxo1 are two PI-3K-regulated targets that 
play important roles but to different extents depending on the specific mitogen. These 
results suggest a model for integrating signals from the innate and the adaptive immune 
systems in the control of the B cell immune response.  
 
 
SIGNIFICANCE 
 
Clonal expansion of antigen-specific B cells during an immune response is necessary for 
effective antibody production. B cells must integrate signals from their clonally-restricted 
B cell antigen receptor (BCR) and from non-clonal co-receptors that provide contextual 
cues to the nature of the antigen. How this is accomplished is unclear. We found that B 
cells require expression of the BCR for mitogenic responses triggered by co-receptors that 
recognize innate or T cell-derived signals. The signaling pathway used by the BCR to 
license co-receptor-induced proliferation is similar to the previously described BCR-
dependent survival signal and, thus, couples B cell survival and mitogenic responses in an 
unexpected manner that may have implications for B cell lymphomagenesis. 
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INTRODUCTION 
 
Expression of a functional B cell antigen receptor (BCR) is of central importance to nearly 
every aspect of B cell biology. During early development, B-lineage cells assemble 
clonally restricted immunoglobulin (Ig) heavy and light chains that are able to recognize a 
diverse and unpredictable universe of antigens. The proper assembly and expression of a 
BCR is a prerequisite for entry into the naïve compartment. Furthermore, naïve resting B 
cells remain dependent on the expression of a correctly assembled BCR. If this is 
prevented by IgH chain ablation or Igα truncation, the cells rapidly undergo apoptosis. 
This has been interpreted to reflect a BCR-dependent ‘tonic’ survival signal, which has 
recently been shown to involve phosphoinositidyl 3-kinase (PI-3K) activity and 
subsequent inactivation of the Foxo1 transcription factor (1-3). 
 
As a consequence of the large clonally restricted repertoire generated during development, 
only a small number of newly generated B cells entering the peripheral mature 
compartment express a BCR that is able to bind a given antigen. During the early stages of 
an immune response, antigen-specific B cells proliferate extensively and increase the 
number of cells that can respond appropriately. The magnitude, duration and quality of the 
B cell response is guided by signals from co-receptors expressed by B cells such as Toll-
like receptors (TLRs) and CD40, which provide information to the B cell about the 
context of the antigen in T cell-independent and -dependent responses (4, 5). Given that 
the raison d’être of B cells is an antigen-specific response including the production of 
antibodies, a central role for the BCR in regulating B cell responses to innate or T cell-
derived signals seems likely. Indeed, early experiments addressing the in vitro response of 
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mouse B cells to bacterial lipopolysaccharide (LPS) have suggested cooperation of LPS 
stimulation and BCR engagement in the proliferative B cell response under certain 
conditions (6, 7). More recent work has uncovered a synergy between TLR and BCR in 
the control of class-switch recombination in activated B cells (8) and the role of the BCR 
in the delivery of DNA- or RNA-associated autoantigens to endosomal TLRs in 
autoimmunity is well established (9). How B cells integrate signals from the BCR and 
from co-receptors responding to mitogenic stimuli in the induction of the proliferative 
response is unclear though. 
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RESULTS AND DISCUSSION 
 
Generation of resting BCR-negative B cells. We generated resting B cells that lack 
expression of the BCR by transducing splenic B cells from bcl-2tg mice that express a 
loxP-flanked pre-rearranged variable domain targeted into the Igh locus (B1-8f) (2) with 
cell-permeable Cre recombinase, TAT-Cre (10). The transduced cells remained alive 
throughout the culture due to ectopic expression of Bcl-2 and lost BCR expression by day 
3 in culture with an efficiency of 30–50%, allowing simultaneous analysis of B cells that 
either express or lack the BCR (BCRpos and BCRneg B cells, respectively; Fig. 1A). 
Western blot analysis of sorted BCRpos and BCRneg B cells confirmed the loss of IgH 
chain expression in the latter (Fig. 1B). The proportion of BCRpos and BCRneg B cells 
remained constant for at least 2 weeks, suggesting that the two classes of cells survive 
equally well in vitro (Fig. S1). Although mature BCRneg cells are slightly smaller than 
their BCRpos counterparts and downregulate some mature B cell markers (e.g. MHC class 
II and CD22), they largely maintain the surface phenotype of resting, mature B cells (Fig. 
1C). 
 
BCR expression is necessary for the mitogenic response of B cells. B cells express 
receptors such as TLR-9, TLR-4 and CD40 that induce activation and proliferation when 
triggered by natural ligands or agonist antibodies (11-13). We tested the proliferative 
response of BCRpos and BCRneg B cells to CpG DNA, LPS or anti-CD40 and found that, in 
contrast to BCRpos B cells, BCRneg B cells did not proliferate in response to any of these 
stimuli (Fig. 2A). This defect is not an artifact of protein transduction since bcl-2tg BCRneg 
B cells generated by a tamoxifen-inducible Cre (14) or in vivo with a mature B cell-
specific Cre-transgene (CD21-Cre) (1) showed the same proliferation defect (Fig. S2). 
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BCRneg B cells are not completely refractory to the mitogenic stimuli, since they activate 
normal NF-κB DNA binding activity in response to CpG (Fig. S3) and upregulate CD69 
and MHC class II when stimulated with CpG DNA, LPS or anti-CD40 (Fig. 2B). Taken 
together, these data show that mature B cells that have lost expression of the BCR are 
responsive to innate stimuli but are unable to proliferate. 
 
BCR expression licenses B cell proliferation through PI-3K activation. Previous 
studies demonstrated that constitutive, low-level signaling, a so-called ‘tonic’ signal, 
which is dependent on an intact BCR, is necessary for mature B cell survival (1, 2) and is 
mediated by the PI-3K/Akt/Foxo1 signaling pathway (3). The requirement of BCR 
expression for mitogenic responses of B cells to innate stimuli raised the possibility that 
the same ‘tonic’ signal may also regulate B cell proliferation. BCRneg B cells generated in 
vivo with a mature B cell-specific Cre-transgene (i.e. CD21-Cre) (1) were used to study 
Akt status in vivo. Indeed, while intracellular staining for phospho-Akt (Ser473) of CpG-
treated BCRpos B cells showed prolonged activation of the PI-3K pathway, induced Akt 
phosphorylation was not seen in BCRneg B cells under these conditions (Fig. 3A). This was 
confirmed by Western blot analysis of sorted BCRpos and BCRneg B cells cultured with or 
without CpG-containing medium for 2 hours (Fig. 3B). We conclude that expression of 
the BCR as mediated by the IgH chain is required for mitogen-induced activation of the 
PI-3K pathway in response to CpG stimulation. To further test the role of BCR-dependent 
PI3K signaling in regulating mitogen-induced proliferation of B cells, we isolated BCRneg 
B cells from B1-8f, CD21-Cre mice that also carried a transgene for an active PI-3K 
molecule that was induced by Cre activity (B1-8f, CD21-Cre, P110*) (3). Expression of 
Cre in mature B cells simultaneously ablates expression of the BCR and induces 
expression of constitutively active PI-3K, which substitutes for the BCR-dependent 
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survival signal (3). Similar to control BCRpos B cells, BCRneg B cells expressing 
constitutively active PI-3K proliferated in response to all of the stimuli (Fig. 3C), showing 
that reconstitution of the PI-3K pathway in BCRneg B cells licenses mitogenic responses to 
innate stimuli.  
 
Inactivation of glycogen synthase kinase (GSK) 3β is necessary for the proliferative 
mitogenic response of BCRneg B cells to CpG. Next, we investigated the BCR-dependent 
signaling pathways downstream of PI-3K as required for mitogenic responses of B cells. 
PI-3K/Akt activates several downstream signaling pathways including pathways utilizing 
GSK3β and Foxo1. GSK3β is a constitutively active serine/threonine kinase that inhibits 
proliferation by phosphorylating and targeting for degradation proteins that are necessary 
for mitosis, including c-Myc (15) and D-type cyclins (16). Mitogenic signals activate the 
PI-3K/Akt pathway, leading to phosphorylation and inactivation of GSK3β (17), thereby 
allowing accumulation of cell cycle regulated proteins. Consistent with defective Akt 
phosphorylation in BCRneg B cells, the levels of phospho-GSK3β remained low in BCRneg 
B cells, in contrast to BCRpos B cells, after treatment with CpG (Fig. 4A), suggesting that 
GSK3β remained active in BCRneg B cells. To directly assess whether GSK3β activity 
prevents the proliferation of mitogen-treated BCRneg B cells, we added the GSK3β 
inhibitor BIO (18) to CpG-stimulated cultures and found that inhibition of GSK3β 
partially restores the ability of bcl-2tg BCRneg B cells to proliferate in response to CpG 
(Fig. 4B). We also found that CpG-induced c-Myc protein levels were much lower in 
BCRneg B cells than those seen in BCRpos B cells treated in a similar manner (Fig. 4C). 
Similar results were seen when LPS or anti-CD40/IL-4 were used as mitogens (Fig. 4C). 
In contrast, mitogen-induced c-Myc mRNA levels were nearly identical between BCRpos 
and BCRneg B cells stimulated with CpG (Fig. S4), suggesting that active GSK3β was 
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destabilizing c-Myc protein in BCRneg B cells (15). Unfortunately, pharmacological 
inhibition of GSK3β activity using BIO, which partially restores proliferation in response 
to CpG (Fig. 4B), did not substantially restore mitogen-induced c-Myc protein expression 
in BCRneg B cells (Fig. 4D). Therefore, we conclude that the decreased levels of c-Myc 
induction in BCRneg B cells, while of potential interest, do not explain the defective 
proliferation of B cells that have lost expression of their BCR. Furthermore, inhibition of 
GSK3β did not rescue proliferation of BCRneg B cells in response to LPS or anti-CD40/IL-
4 treatment (Fig. 4E), suggesting that BCR-dependent PI-3K activation regulates 
additional signaling pathways required for mitogenic responses, depending on the 
stimulus.  
 
Foxo1 and GSK3β regulate innate stimuli-induced mitogenic responses downstream 
of the BCR. Inactivation of the transcription factor Foxo1 by BCR-dependent PI-3K/Akt 
activation is necessary for mature B cell survival (3). The complete loss of Foxo1 rescues 
the survival of BCRneg B cells as efficiently as expression of active PI-3K, whereas loss of 
one Foxo1 allele is sufficient for a partial rescue of BCRneg B cells (3). Since Foxo1 
remains active in BCRneg B cells (3) and can inhibit proliferation by up-regulating anti-
proliferative genes (19, 20), we tested the effect of Foxo1 ablation on mitogen-treated 
BCRneg B cells. BCRneg B cells that were either heterozygous or homozygous for a Foxo1-
null allele were sorted, and their proliferative responses in the absence or presence of BIO 
to inhibit GSK3β were compared to mitogen-stimulated BCRpos cells (Fig. 5). While the 
complete or partial loss of Foxo1 had only minimal effects on the proliferative response of 
BCRneg B cells to CpG, the combination of Foxo1 deletion and inhibition of GSK3β 
rescued the proliferation of BCRneg B cells in response to CpG to a level comparable to 
that observed by CpG-stimulated BCRpos B cells. In contrast, while heterozygous deletion 
 9 
of Foxo1 was sufficient for some anti-CD40/IL-4-treated BCRneg B cells to undergo at 
least one cell division, homozygous deletion of Foxo1 allowed near-complete rescue of 
BCRneg proliferation to anti-CD40/IL-4. In both cases, inhibition of GSK3β had little 
additional effect, suggesting that different mitogens require PI-3K to activate different 
signaling pathways for proliferation in the absence of BCR expression (Fig. 5). To further 
illustrate this point, BCRneg B cells on a Foxo1-null background in the presence of a 
GSK3β inhibitor remained unable to proliferate in response to LPS treatment (Fig. 5), 
suggesting that other or additional pathways downstream of PI-3K/Akt that regulate cell 
proliferation are involved. 
 
Our experimental model is based on previous evidence that the BCR expressed by resting, 
mature B cells provides ‘tonic’ survival signals to the cells (1, 2). The mechanism by 
which such signals are initiated is controversial, but may involve low-affinity interactions 
of the BCR with environmental antigens, akin to the positive selection of T cells by self-
MHC. It is also possible, however, that loss of the BCR induces a danger signal in the 
cells from which they can be relieved by PI-3K pathway activation. By extending the 
analysis to the control of B cell proliferation, the present data provide the elements of a 
molecular mechanism by which the BCR controls the proliferative expansion of B cells 
upon engagement of invariant, ‘innate’ receptors. Such a crosstalk between these two 
classes of receptors reflects the physiological requirement of integrating, in any 
meaningful antibody response, input from the BCR regarding specific antigen recognition 
and information about the nature and context of the immunizing antigen, the latter being 
provided to the cells by innate receptors like TLRs recognizing pathogen-associated 
molecular patterns presented by microbes and the CD40 co-receptor which is triggered by 
T helper cells. The requirement of this regulatory principle is particularly obvious in the 
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case of the somatic antibody mutants generated in the germinal center reaction, whose 
expansion through T cell-derived and innate signals should strictly depend on newly 
acquired BCR specificities, or BCR expression in the first place. 
  
Although receptor-proximal signaling events in B cells differ among TLRs and CD40, 
these receptors share common downstream signaling pathways, such as the PI-3K, MAPK 
and NF-κB pathways (21, 22). This is supported by the similarity of gene expression 
profiles of primary B cells stimulated with distinct mitogenic agonists (23). The BCR 
appeared to specifically control PI-3K signaling in the cells, in that a key PI-3K target, 
Akt, was not phosphorylated in BCRneg cells upon CpG stimulation (Fig. 3B), and 
expression of active PI-3K rescued mitogenic reponses in the absence of the BCR (Fig. 
3C). The BCR is apparently involved in this process in mitogen-activated B cells, 
conceivably by controlling the levels, activity or localization of inhibitors of the PI-3K 
pathway. This scenario is supported by results showing that mature B cells undergoing 
Cre-mediated BCR deletion in vivo can be rescued from apoptosis by expression of 
constitutively active PI-3K as well as by the ablation of PTEN, a lipid phosphatase that 
directly opposes PI-3K activity (24). Downstream of PI-3K activation, the signaling 
pathways diverge depending on the specific mitogen. Inactivation of Foxo1 is important 
for proliferation in response to anti-CD40/IL-4 stimulation, whereas inactivation of 
GSK3β plays a greater role in the mitogenic response to CpG. Interestingly, inactivation 
of both GSK3β and Foxo1 are not sufficient for LPS-induced proliferation, suggesting that 
additional BCR-dependent signaling pathways are activated by PI-3K that are necessary 
for TLR4-mediated proliferation of B cells. The present results indicate that, in addition to 
its role in the control of B cell survival, BCR modulation of PI-3K signaling licenses the 
induction of clonal expansion of B cells by mitogens acting on innate receptors expressed 
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by the cells, a process of crucial importance in the antibody response. In this scenario, 
BCR engagement by self- or cognate antigen as well as cross-reactivity with mitogens (8) 
may well play a modulating role. Quite fittingly, the work of Pone et al. has identified an 
interplay between BCR and TLR signaling in the control of class-switch recombination in 
the activated B cells. This was mediated by NF-κB signals downstream of both receptors, 
which, significantly, depended on PI-3K activity in the case of the BCR (8). 
 
The integration of signals delivered by distinct cellular receptors is an obvious 
requirement for any cellular response in multicellular organisms. An example is the 
outside-in signaling of integrins bound to extracellular matrix proteins, which mediate the 
proliferation of adherent epithelial cells in response to growth factors (25). Notably, the 
PI-3K pathway plays a role in this context as well, and also provides integrin-activated 
pro-survival signals to the adherent cells (26, 27). The interplay between the antigen 
receptor and innate immune receptors, which we have described here for B lymphocytes, 
may thus be just a variation of an ancient principle of receptor crosstalk in higher cells. It 
will be interesting to see whether this crosstalk also plays a role in the homeostasis of 
memory cells and to which extent and by what means the BCR also licenses the 
proliferative expansion of B cell lymphomas (28). 
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MATERIAL AND METHODS 
 
Mouse strains. B1-8f (2), JHT (29), bcl-2tg (30), CD21-Cre (1), rosa26-stopf-P110* (3), 
and Cre-ED4 (14) mice were housed and maintained under specific pathogen-free 
conditions. All mouse protocols were approved by Harvard University and the Immune 
Disease Institute Institutional Animal Care and Use Committees. 
 
Cell culture and TAT-Cre transduction. TAT-Cre (also known as HTNC, expression 
plasmid available from Addgene) was produced as described (10). Purified B cells were 
washed three times in serum-free, ADCF medium (Hyclone), prewarmed to 37°C, and 
transduced with 50 µg/ml TAT-Cre in the presence of 50 µg/ml polymyxin B sulfate 
(Sigma-Aldrich) at a density of 5x106/ml for 45 min at 37°C. Cells were then washed in 
complete medium [DMEM supplemented with 10% FCS (Biowhittacker), 10 mM 
HEPES, 2 mM L-glutamine, 1 mM sodium pyruvate, 1X penicillin/streptomycin, 1X non-
essential amino acids (Cellgro), and 50 µM β-mercaptoethanol] and cultured at 37°C for 
3–5 days at 2x106/ml in complete medium. Mock-transduced cells were treated identically 
except that TAT-Cre was omitted. B cells were labeled with CFSE, as indicated, by 
washing two times in PBS, prewarming for 10 min at 37°C, and incubation with titrated 
amounts of CFSE for 10 min at 37°C. Cells were washed in complete medium and 
stimulated with 1 µg/ml anti-CD40 (1C10, eBioscience), 20 µg/ml ultrapure LPS 
(InvivoGen), or 645 ng/ml CpG (ODN1826, InvivoGen) at 2x105/ml in complete medium 
for 3–4 days. The GSK3 inhibitor BIO or the inactive control Meth-BIO (Calbiochem) 
were added at a concentration of 0.2 µM as indicated. 
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FACS. Single cell suspensions of ex vivo splenocytes or cultured B cells were stained 
with antibodies to IgM (goat Fab, Jackson ImmunoResearch), IgD (1.3-5), Igκ (R33-
18.10), Igβ (HM79), CD19 (1D3), B220 (RA3-6B2), CD22 (CY34), CD21 (7G6), CD23 
(B3B4), CD24 (M1/69), CD95 (Jo2), CD93 (AA4.1), I-Ab (AF6-120), or CD69 (H1.2F3). 
Dead cells were excluded by addition of ToPro3 (Invitrogen). For intracellular staining, 
cells were fixed and permeablized with Perm/Fix and Perm/Wash solutions (BD 
Bioscience) according to manufacturer’s instructions, stained with anti-phospho-Akt 
(S473, Cell Signaling) or anti-phospho-GSK3α/β (37F11, Cell Signaling) and detected 
with anti-rabbit-FITC. Data was collected on a FACScalibur (BD Bioscience) and 
analyzed with CellQuest (BD Bioscience) or FlowJo (TreeStar) software. 
 
Cell separation. Red blood cells were lysed by hypotonic shock from splenocyte 
suspensions. B cells were purified by CD43-depletion using MACS (Miltenyi). For some 
experiments, BCRneg B cells were isolated by MACS depletion of IgM+ B cells from 
TAT-Cre-transduced cultures using biotinylated anti-IgM (331-12) and streptavidin-beads 
(Miltenyi). Purity was >98% as determined by IgD staining. Alternatively, B cells were 
stained with Fab anti-IgM and anti-B220 before FACS sorting on an Aria2 or 
FACSvantage (BD Bioscience). 
 
Immunoblot analysis. Whole cell lysates were prepared in lysis buffer [40 mM Tris (pH 
7.6), 150 mM NaCl, 2 mM EDTA, 1% NP40, 0.25% sodium deoxycholate, 1X EDTA-
free protease inhibitor cocktail (Roche), 1 mM PMSF, 5 mM NaF, 0.5 µM, 1 mM 
Na3VO4]. The protein concentration was determined by detergent compatible protein 
assay kit (Bio-Rad). Equal amounts of protein were separated by SDS-PAGE and 
transferred to PVDF membranes (Millipore). The membranes were immunoblotted, as 
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indicated, with phospho-Akt (S473), Akt (Cell Signaling), c-Myc (Epitomics), β-actin 
(Sigma-Aldrich) or biotinylated goat Fab anti-mouse IgM (Jackson ImmunoResearch). 
 
NF-κB EMSA. Splenic B cells from B1-8f/JHT, bcl-2tg mice were TAT-Cre-transduced 
and placed in culture for 3 days. Purified BCRpos and BCRneg B cells were then cultured 
overnight in 1% FCS-containing medium prior to addition of CpG for the indicated 
amounts of time. Cells were lysed in buffer A (5 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 
mM KCl, 0.5 mM DTT and protease inhibitors) to prepare cytosolic extracts and nuclei. 
Nuclear extracts were subsequently prepared using buffer C (20 mM HEPES pH 7.9, 25% 
glycerol, 0.5 M NaCl, 1.5 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT and protease 
inhibitors). Nuclear extracts were incubated with competitor DNA (pdIdC, Sigma) and 
a 32P labeled-κB consensus probe (Promega). Protein-DNA complexes were then resolved 
by electrophoresis on a non-denaturing polyacrylamide gel. 
 
Quantitative RT-PCR. RNA was purified using mirVana RNA isolation kit (Ambion) 
and subjected to cDNA synthesis using random hexamer primers (Invitrogen). 
Quantitative RT-PCR analysis was performed using c-myc- and hprt-specific primers on a 
StepOne Plus (Applied Biosystems) machine. Primers used were: c-MycF1, 5’-
gagcccctagtgctgcatgag-3’; c-MycR1, 5’-ttgcctcttctccacagacacc-3’; HPRTF1, 5’-
ctataagttctttgctgacctgctggattaca-3’; HPRTR1, 5’-ccagttaaagttgagagatcatctccaccaataact-3’. 
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FIGURE LEGENDS 
 
Fig. 1. In vitro generation of BCRneg B cells. (A) Schematic showing Cre-mediated 
deletion of the loxP-flanked B1-8 allele and subsequent loss of BCR expression. (B) 
Splenic B cells from B1-8f/+, bcl-2tg mice were treated with recombinant TAT-Cre for 45 
min, cultured for 9 days, and sorted by FACS to >98% purity based on IgM expression 
(data are representative of two biological replicates). Serial dilutions of whole cell lysates 
starting at 300,000 cell equivalents were analyzed for Igµ and β-actin expression by 
Western blotting. (C) Splenic B cells from B1-8f/+, bcl-2tg mice were transduced with 
TAT-Cre for 45 min, cultured for 5 days in medium, and stained for CD19, IgM, and the 
indicated surface markers (data are representative of three biological replicates). BCRpos 
cells (open histograms) and BCRneg cells (closed histograms) were gated as shown.  
 
Fig. 2. Expression of the BCR is necessary for B cell proliferation. BCRpos and BCRneg B 
cells were generated by TAT-Cre transduction of B cells from B1-8f/+, bcl-2tg mice. 
After 3 days in culture, cells were either (A) labeled with CFSE and stimulated for 3–4 
days (data are representative of five biological replicates) or (B) stimulated for 24 hrs with 
the indicated mitogen and analyzed by FACS (data are representative of two biological 
replicates). Live cells were gated as ToPro3-, CD19+. 
 
Fig. 3. Defective activation of PI-3K in BCRneg B cells. (A) Splenic B cells from B1-
8f/JHT, bcl-2tg or B1-8f/JHT, CD21-Cre, bcl-2tg mice were stimulated with CpG for the 
indicated times and stained for CD19 and IgM and intracellular phospho-Akt (Ser473). 
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BCRpos (green) cells were gated from B1-8f/JHT, bcl-2tg cells, while Cre+ BCRpos (red) or 
Cre+ BCRneg (blue) B cells were gated from B1-8f/JHT, CD21-Cre, bcl-2tg cells. 
Normalized mean fluorescence intensity values for phospho-Akt (Ser473) are shown. Data 
represent three biological replicates. (B) BCRpos and BCRneg B cells were sorted from B1-
8f/JHT, bcl-2tg splenic B cells 5 days after transduction with TAT-Cre, placed in culture 
overnight and stimulated with CpG for 2 hrs. Equal amounts of cytoplasmic lysates were 
blotted for phospho-Akt (Ser473) and Akt. Data are representative of two biological 
replicates. (C) Splenic BCRpos and GFP+ BCRneg B cells were sorted from Rag2∆/∆, cγ-/- 
mice that had been reconstituted with fetal liver from B1-8f/JHT, CD21-Cre, P110* mice, 
labeled with CFSE and cultured for 3 days in medium (black) or medium plus the 
indicated stimulus (red). Data are representative of three biological replicates. 
 
Fig. 4. GSK3β activity prevents the proliferation of CpG-treated BCRneg B cells. (A) 
Splenic B cells from B1-8f/JHT, bcl-2tg or B1-8f/JHT, CD21-Cre, bcl-2tg mice were 
stimulated with CpG for the indicated times and stained for CD19 and IgM and 
intracellular phospho-GSK3α/β (S21/9). BCRpos (green) cells were gated from B1-8f/JHT, 
bcl-2tg cells, while Cre+ BCRpos (red) or Cre+ BCRneg (blue) B cells were gated from B1-
8f/JHT, CD21-Cre, bcl-2tg cells. Normalized mean fluorescence interval values for 
phospho-GSK3α/β (S21/9) are shown. Data represents three biological replicates. (B) B 
cells from B1-8f/JHT, CD21-Cre, bcl-2tg mice or TAT-Cre transduced B cells from B1-
8f/JHT, bcl-2tg mice were CFSE labeled and stimulated for 3 days with CpG alone (green) 
or with Meth-BIO (inactive control inhibitor, red) or BIO (GSK3 inhibitor, blue). Cells 
were gated on ToPro3-, CD19+ and IgM+ or IgM-. Data are representative of three 
biological replicates. (C) Splenic B cells from B1-8f/+, bcl-2tg mice were TAT-Cre 
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transduced and cultured for 3 days. Purified BCRpos and BCRneg B cells were placed in 
culture overnight and stimulated with CpG, LPS or anti-CD40/IL-4 for 6 hrs. Equal 
amounts of protein from whole cell lysates were used for Western blotting with the 
indicated antibodies. Data are representative of three biological replicates. (D) Sorted 
BCRpos and BCRneg B cells from B1-8f/+, CD21-Cre, bcl-2tg mice were cultured in 
medium, CpG or CpG and BIO for 6 hrs. Lysates were analyzed by Western blot for c-
Myc and β-actin levels. Data are representative of three biological replicates. (E) Splenic 
BCRpos and BCRneg B cells from B1-8f/+, CD21-Cre, bcl-2tg mice were sorted, labeled 
with CFSE and cultured in media or with LPS or anti-CD40/IL-4 alone (red) or with BIO 
(blue). Data are representative of three biological replicates. 
 
Fig. 5. Foxo1 deletion plus GSK3β inhibition rescues proliferation in CpG-treated BCRneg 
B cells. Splenic B cells were sorted, labeled with CFSE and cultured either in medium 
(green) or with the indicated stimuli, with (blue) or without (red) the GSK3β inhibitor 
BIO. BCRpos, Foxo1f/+ and BCRneg Foxo1∆/+ cells were sorted from B1-8f/JHT, CD21-
Cre, Foxo1f/+ mice, while BCRneg, Foxo1∆/∆ cells were sorted from B1-8f/JHT, CD21-
Cre, Foxo1f/f mice. Data are representative of three biological replicates. 
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SUPPORTING INFORMATION FIGURE LEGENDS 
Fig. S1. Expression of Bcl-2 rescues survival of BCRneg B cells in vitro. Purified Splenic 
B cells were transduced with TAT-Cre for 45 min and cultured in vitro. After 4 or 14 
days, cells were analyzed for a change in the proportion of ToPro3-, CD19+ B cells that 
lost expression of IgM and IgD. Data are representative of three biological replicates. 
Fig. S2. Defective proliferation of BCRneg B cells. (A) B cells from B1-8f/+, ED-Cre, bcl-
2tg mice were purified and treated with 4-OH Tamoxifen for 7 days prior to CFSE 
labeling and stimulation with the indicated mitogen for 3 days. Data are representative of 
three biological replicates. (B) Ex vivo isolated B cells from B1-8f/JHT, CD21-Cre, bcl-2tg 
mice were labeled with CFSE and cultured in medium or with CpG for 3 days. ToPro3-, 
CD19+ cells are shown. Data are representative of two biological replicates. 
Fig. S3. Stimulation with CpG induces normal NF-κB DNA-binding activity in BCRneg B 
cells. BCRpos and BCRneg B cells from B1-8f/+, bcl-2tg mice were cultured overnight in 
1% FCS-containing medium and stimulated for the indicated times with CpG. Nuclear 
lysates were used for EMSA. The data presented here was biologically replicated once 
using the 0 and 120 minutes time points. 
Fig. S4. Normal induction of c-myc transcription in CpG-stimulated BCRneg B cells. 
Sorted BCRpos and BCRneg B cells generated by TAT-Cre transduction from B1-8f/+, bcl-
2tg mice were stimulated for 3 hrs with medium or CpG. cDNA from purified RNA was 
used for quantitative rtPCR analysis of c-myc and hprt expression. Data for two 
biologically independent experiments (average of technical duplicates shown for each 
biologically independent experiment) represent fold-change of c-myc expression relative 
to BCRpos B cells cultured in medium. 
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